 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 11, 2022 GLOBE NEWSWIRE -- Molecular Partners AG SIX: MOLN; NASDAQ: MOLN, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that members of its management team will participate in two upcoming investor events. In addition, the Company will publish its Q1 2022 earnings report on May 12, after the close of trading at the NASDAQ exchange. 